Business
    Next Score View the next score

    mass. movers

    Aegerion climbs a second straight day

    Aegerion’s Juxtapid drug is used to treat cholesterol disease.
    istockphoto.com
    Aegerion’s Juxtapid drug is used to treat cholesterol disease.

    Aegerion Pharmaceuticals Inc. rose on Tuesday and Wednesday even after it posted a wider net quarterly loss of $18.9 million amid higher expenses. Aegerion raised its revenue expectations for the year to reflect recent results from the launch of its genetic cholesterol-disease drug, Juxtapid, its sole product on the market. Aegerion raised its net revenue expectation to $30 million to $35 million, from earlier guidance of $15 million to $25 million.

    Advertisement